Nuvation Bio IncNYSE:NUVB
- LAST PRICE3.0450
- TODAY'S CHANGE (%)-0.1150 (-3.6392%)
- Bid / Lots3.0400/ 17
- Ask / Lots3.0500/ 15
- Open / Previous Close3.1500 / 3.1600
- Day Range
- 52 Week Range
- Volume145,165
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NUVB |
|---|---|---|
| 09:32 ET | 7520 | 3.17 |
| 09:34 ET | 3007 | 3.15 |
| 09:36 ET | 700 | 3.145 |
| 09:38 ET | 500 | 3.135 |
| 09:39 ET | 17705 | 3.12 |
| 09:41 ET | 19779 | 3.095 |
| 09:43 ET | 4491 | 3.0692 |
| 09:45 ET | 13778 | 3.06 |
| 09:48 ET | 3217 | 3.05 |
| 09:50 ET | 1224 | 3.05 |
| 09:52 ET | 3200 | 3.055 |
| 09:54 ET | 20318 | 3.0674 |
| 09:56 ET | 6365 | 3.065 |
| 09:57 ET | 20596 | 3.04 |
| 09:59 ET | 7195 | 3.035 |
| 10:01 ET | 3986 | 3.045 |
| 10:03 ET | 600 | 3.045 |
Jun 3, 2024
DJ Nuvation Bio Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 6:46AM ET on Monday Jun 03, 2024 by Dow Jones
6:46AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nuvation Bio Inc | 781.1M | -9.7x | --- |
89Bio Inc | 763.5M | -3.8x | --- |
Perspective Therapeutics Inc | 754.6M | -6.8x | --- |
CARGO Therapeutics Inc | 733.6M | -5.6x | --- |
Hillevax Inc | 717.0M | -4.4x | --- |
Viridian Therapeutics Inc | 843.1M | -2.9x | --- |
Company Information
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Contact Information
- Headquarters
- 357 Tehama Street, Floor 3SAN FRANCISCO, CA, United States 94103
- Phone
- 415-754-3517
- Fax
- 302-636-5454
Executives
- Independent Chair of the Board
- Daniel Welch
- President, Chief Executive Officer, Founder, Director
- David Hung
- Principal Financial and Accounting Officer, Vice President - Finance
- Moses Makunje
- Chief Executive Officer of AnHeart Therapeutics and Director
- Junyuan Wang
- Chief People Officer
- Stacy Markel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $781.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
